ImmunoGen Announces New License Agreement with Novartis
October 11, 2013 at 06:54 AM EDT
ImmunoGen (NASDAQ: IMGN ) today announced that Novartis (NYSE: NVS ) has licensed the exclusive right to use the Company's ADC technology to develop anticancer therapeutics to an undisclosed target.